A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Fasiglifam (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 27 Dec 2013 Status changed from recruiting to discontinued, as reported by a Takeda media release.
- 17 Mar 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-002741-35).
- 25 Oct 2011 New trial record